On September 30, the House Energy and Commerce Committee is holding a hearing on draft drug safety legislation authored by Reps. John Dingell, Henry Waxman, Frank Pallone, and Bart Stupak. The bill would require parity between foreign and domestic drug facility inspections, increase the number of pre-approval drug inspections, prohibit the entry of drugs into the United States lacking documentation of safety, require manufacturers to ensure the safety of their supply chain, and grant the FDA authority to mandate recalls of unsafe drugs.